Sumitomo Dainippon Pharma Aktie
| 3,62EUR | 0,10EUR | 2,84% |
WKN: 858257 / ISIN: JP3495000006
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Sumitomo Chemical Co., Ltd. | 51,68 |
| Freefloat | 38,73 |
| Nomura Asset NEXT FUNDS NIKKEI 225 ETF (1321) | 2,24 |
| Inabata & Co., Ltd. | 2,21 |
| Nippon Life Insurance Co. | 1,91 |
| Sumitomo Mitsui Banking Pension Fund | 1,76 |
| Sumitomo Life Insurance Co. | 1,45 |
| Nomura Asset NEXT FUNDS TOPIX ETF (1306) | 1,31 |
| Nikko Exchange Traded Index Fund 225 | 1,08 |
| Daiwa Asset iFreeETF NIKKEI 225 (Yearly Dividend Type) (1320) | 1,01 |
| Sumitomo Pharma Employee Stock Ownership Plan | 0,91 |
| Arcus Japan Fund | 0,71 |
| MS&AD Insurance Group Holdings, Inc. | 0,67 |
| Ono Pharmaceutical Co., Ltd. | 0,54 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 6 457 | 6 822 | 6 987 | 6 250 | 4 980 |
| Umsatz pro Mitarbeiter in Mio. EUR | 74,76 | 75,63 | 80,15 | 88,89 | 63,16 |
Bilanz (in Mio. JPY) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 364 090 | 459 795 | 499 521 | 381 860 | 269 569 |
| Summe Anlagevermögen | 888 788 | 848 332 | 808 486 | 752 882 | 637 937 |
| Summe Aktiva | 1 252 878 | 1 308 127 | 1 308 007 | 1 134 742 | 907 506 |
Bilanz (in Mio. JPY) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 315 259 | 290 680 | 284 544 | 346 372 | 427 864 |
| Summe Fremdkapital | 620 773 | 659 949 | 634 438 | 727 960 | 751 370 |
| Summe Eigenkapital | 632 105 | 648 178 | 673 569 | 406 782 | 156 136 |
| Summe Passiva | 1 252 878 | 1 308 127 | 1 308 007 | 1 134 742 | 907 506 |
Adresse
| 2-6-8 Dosho-machi, 541-0045 Osaka | |
| Telefon | +81 (6) 6203-5321 |
| Fax | +81 (6) 6202-6028 |
| Internet | http://www.ds-pharma.co.jp/ |
Management
|
Atsuko Higuchi
Head-Secretariat, Personnel & Public Relations |
|
Hiroshi Niinuma
Non-Executive Director |
|
Hiroyuki Baba
Managing Executive Officer & Head-Legal Affairs |
|
Hisayoshi Kashima
Manager-Accounting |
|
Isao Shimizu
Executive Officer & Senior Research Director |
|
Kazuo Koshiya
Managing Executive Officer |
|
Kenji Ueno
Executive Officer & GM-Technology Research |
|
Koji Fujimoto
Outside Director |
|
Minoru Usui
Outside Director |
|
Motoyuki Sakai
Representative Director & EVP-Human Resources |
|
Nobuhiro Endo
Independent Outside Director |
|
Saeko Arai
Independent Outside Director |
|
Shigeyuki Nishinaka
Managing Executive Officer |
|
Takashi Kutsunai
Auditor |
|
Takuya Taguchi
Managing Executive Officer & General Manager-Sales |
|
Toru Kimura
President, CEO & Representative Director |
|
Tsutomu Nakagawa
Director & Executive Officer |
|
Yoshiharu Ikeda
Head-Research & Technology |
|
Yoshinori Ooe
Auditor |
|
Yutaka Wakemi
Executive Officer, VP & Head-Global Strategy |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
